Neuroses Except Depressive DRG Reimbursement & Medicare

Summary & Overview

Neuroses Except Depressive: Inpatient Reimbursement Overview

DRG 882 encompasses inpatient stays for nondepressive neuroses such as anxiety and somatoform disorders and defines the clinical grouping used to assign payment. This grouping matters for inpatient reimbursement because it determines the Diagnosis-Related Group payment relative to expected resource use and any documented complications or comorbidities.

Neuroses Except DepressiveDRG Neuroses Except DepressiveDRG 882Diagnosis-Related GroupInpatient ReimbursementMedicareBehavioral HealthPsychiatryMental Health Admission

DRG 882 Overview

DRG 882 covers inpatient admissions for primary diagnoses of anxiety disorders, phobic disorders, somatoform disorders, and other nonpsychotic neuroses excluding primary depressive disorders. This Diagnosis-Related Group captures cases where the principal reason for hospitalization is management of these neurotic conditions, often involving stabilization, medication adjustment, and assessment of psychosocial risk. It matters for Medicare payment because grouping determines payment assignment based on clinical category and resource use intensity rather than specific therapies. Accurate coding and documentation of principal diagnosis and any concurrent complications or comorbidities influence reimbursement under Medicare rules.

National Payment Rates

Across commercial payers the observed rate range spans roughly $390 to $28K, with Anthem and BCBS showing lower median levels and Aetna/Cigna having higher medians. The widest spread is between Anthem (min $390, max $20K) and Aetna/Cigna (max $28K), indicating substantial variation across payers; see the table and chart below for payer-specific percentiles. Blue Cross Blue Shield, UnitedHealth Group, Cigna, Aetna, and Anthem are shown in the comparison.

Mean Rates by Payer — National — DRG 882

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska’s DRG 882 reimbursements span from roughly $2.5K at the low end up to $30K at the high end across payers, with most payers clustering in the $12K–$20K range. Cigna stands out with a notably higher mean (~~$20K) and median (~~$17K) compared with Blue Cross Blue Shield and Anthem, which both show medians near ~$12K. This produces a wider top-end deviation versus national medians. See the table and chart below for payer-level detail.

Key Insights for Alaska

Blue Cross Blue Shield is among the lowest-paying payers in Alaska (median ~$12K) while Cigna is the highest-paying payer (median ~$17K; mean ~$20K).
Anthem’s Alaska benchmarks mirror Blue Cross Blue Shield’s (median ~$12K), producing a payer spread from about $2.5K–$30K across payers with Alaska means skewed slightly above some national medians.
The state’s Cigna mean (~$20K) meaningfully exceeds several national payer medians, indicating higher reimbursement at the top end in Alaska.

Clinical Trials

Acute inpatient intervention trials testing short-term psychotherapy or structured behavioral programs delivered during hospitalization to reduce severity of anxiety, panic, dissociative, or somatoform symptoms. These studies enroll patients admitted for acute exacerbations of neuroses (excluding major depressive disorder) and compare different intensive therapy formats or adjunctive noninvasive neuromodulation during the brief stay; findings help hospitals identify effective, resource-feasible interventions that shorten length of stay and reduce symptom burden. This is relevant to providers and payers because improved acute management can lower inpatient days, reduce readmissions, and guide allocation of inpatient behavioral health staffing.
Comparative effectiveness studies conducted in mixed inpatient–outpatient cohorts that evaluate different care pathways (for example, stepped-care models, early discharge with coordinated outpatient follow-up, or integrated primary care behavioral health) for patients with anxiety disorders, conversion/somatoform presentations, and related neuroses. These trials focus on which systems of care produce the best functional outcomes and lowest total cost of care across the 30–90 day post-discharge period, enrolling patients with varying severity and comorbidity to reflect real-world populations. Results inform payers and health systems about which models reduce downstream utilization and improve continuity of care for this DRG population.
Longitudinal outcomes and health services research assessing post-discharge trajectories, relapse rates, healthcare utilization, and work or functional outcomes in patients hospitalized with neuroses except depressive. These observational or pragmatic studies follow patients after discharge to identify predictors of readmission, adherence to outpatient therapy, and the impact of comorbid medical conditions or psychotropic medication patterns on long-term costs and outcomes. Such research is important for designing discharge planning, case management, and reimbursement policies that target high-risk patients to prevent avoidable readmissions and optimize resource use.

Behavioral and Developmental Disorders: Inpatient Reimbursement Overview

887-OTHER-MENTAL-DISORDER-DIAGNOSES

Other Mental Disorder Diagnoses: Inpatient Reimbursement Overview

885-PSYCHOSES

Psychoses: Inpatient Reimbursement Overview

876-O-R-PROCEDURES-WITH-PRINCIPAL-DIAGNOSIS-OF-MENTAL-ILLNESS

O.R. Procedures with Principal Diagnosis of Mental Illness: Inpatient Reimbursement Overview

883-DISORDERS-OF-PERSONALITY-AND-IMPULSE-CONTROL

Disorders of Personality and Impulse Control: Inpatient Reimbursement Overview

881-DEPRESSIVE-NEUROSES

Depressive Neuroses: Inpatient Reimbursement Overview

884-ORGANIC-DISTURBANCES-AND-INTELLECTUAL-DISABILITY

Organic Disturbances and Intellectual Disability: Inpatient Reimbursement Overview

880-ACUTE-ADJUSTMENT-REACTION-AND-PSYCHOSOCIAL-DYSFUNCTION

Acute Adjustment Reaction and Psychosocial Dysfunction: Inpatient Reimbursement Overview

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$8.9K	$36K	$6.7K	1.3K